Latest Breaking News On - Intranasal etripamil using - Page 1 : comparemela.com

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

NDA submission for etripamil in patients with PSVT expected in October 2023Data featured during oral session at Heart Rhythm 2023 Annual Meeting support the potential of etripamil in patients with. -Today at 07:37 am- MarketScreener

United statesDavid pittsJoseph olivetoProgram updatesCenters for diseaseExchange commissionUs securities exchange commissionMilestone pharmaceuticalsCompany phaseDrug administrationPrnewswire milestone pharmaceuticals incMilestone pharmaceuticals incHeart rhythmNew drug applicationChief executive officerEtripamil nasal spray

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes.

United statesDavid pittsBruce stamblerDavid bharuchaKaplan meierUs securities exchange commissionPiedmont heart instituteMilestone pharmaceuticals incExchange commissionMilestone pharmaceuticalsLead authorChief medical officerIntranasal etripamil usingRepeat dose regimenNorth americaAbout paroxysmal supraventricular

Milestone Pharmaceuticals (MIST) Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

Milestone Pharmaceuticals (MIST) Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBruce stamblerDavid bharuchaKaplan meierPiedmont heart instituteMilestone pharmaceuticals incMilestone pharmaceuticalsLead authorChief medical officerIntranasal etripamil usingRepeat dose regimenNew drug application